<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367216">
  <stage>Registered</stage>
  <submitdate>10/10/2014</submitdate>
  <approvaldate>27/10/2014</approvaldate>
  <actrnumber>ACTRN12614001136695</actrnumber>
  <trial_identification>
    <studytitle>Probiotic microflora in the gut following ingestion of fermented milk.</studytitle>
    <scientifictitle>Recovery of faecal Lactobacillus casei strain Shirota (LcS)
from the Intestine of Healthy Adults after Intake of Fermented Milk.
</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nill known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gut microbia in community dwelling adults</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Daily ingestion of a single dose (1 bottle, 65mL) of a commercially available fermented milk product (Yakult), containing 6.5 billion Lactobacillus casei Shirota strain (probiotic) per bottle, for 14 days. Participants will be asked to complete a daily questionnaire to provide details on adherence. </interventions>
    <comparator>Participants will undertake a 14 day baseline washout period where no probiotic supplements are ingested. 

Participants will undertake a 14 day follow up period where no probiotic supplements are ingested.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Recovery of Lactobacillus casei Shirota (LcS) in faeces. LcS will be analysed using culture method (FOM-LLV) and ELISA.</outcome>
      <timepoint>Faecal samples will be analysed at four (4) time-points; 14 days after cessation of probiotic products (baseline); 7 days into the ingestion period (ingestion period 1); 14 days into the ingestion period (ingestion period 2); and 14 days after the ingestion period (follow up).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Stool consistency. Subjects will rate stool consistency based on the Bristol Stool Form Scale and report the findings in a daily participant diary. </outcome>
      <timepoint>Each day during the 42 day trial.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of bowel movements per day. Subjects will report the findings in a daily participant diary.</outcome>
      <timepoint>Each day during the 42 day trial.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Community dwelling adults</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Body mass index less than 18.5 or above 25 kg/m2. 
History of gastrointestinal disorders (constipation, diarrhea, abdominal pain, irritable bowel syndrome).
Disorders requiring a special diet.
Respiratory or gastrointestinal illness in the 30 days prior to the study. 
Use of systemic antibiotics or antimycotics medication in the 30 days prior to the study. 
Use of antidiarrheal or laxative medications in the 30 days prior to the study.
History of asthma or allergies.
Use of immunomodulating medications and participation in any other studies within 2 months prior to entry into the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed.

All subjects undergo the treatment (ingestion of a commercially available fermented milk product). </concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Within subject repeated measures analysis to ascertain the mean effect and 95% confidence intervals. The sample size was chosen based on previous research reporting an increase in Lactobacillus casei strain Shirota after ingestion of fermented milk containing the probiotic for 10-14 days (J Med Assoc Thai. (2012) 95 S42-7; European Journal of Clinical Nutrition (1998) 52, 899-907). A power calculation based on the results from these studies (using and alpha of 0.01 and a desired power of .90) suggests a sample size of 25 will be sufficient to detect statistical significance. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/10/2014</anticipatedstartdate>
    <actualstartdate>24/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>170 Kessels Road, Nathan, QLD 4111</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Yakult Honsha Co., LTD.</fundingname>
      <fundingaddress>1-19 Higashi Shimbashi 1-chrome,
Minato-ku, Tokyo 105-8660</fundingaddress>
      <fundingcountry>Japan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Yakult Honsha Co., LTD.</sponsorname>
      <sponsoraddress>1-19 Higashi Shimbashi 1-chrome,
Minato-ku, Tokyo 105-8660</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to investigate the efficacy of daily supplementation of a commercially available fermented milk product (Yakult) to increase gut microbial content. Specifically, it is hypothesized that ingestion of Yakult for 14 days will increase the concentration of intestinal Lactobacillus casei strain Shirota (LcS) in 25 young healthy adults (18 - 35 yr). </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Griffith University Human Research Ethics Committee</ethicname>
      <ethicaddress>Griffith University, 170 Kessels Road, Nathan, QLD, 4111</ethicaddress>
      <ethicapprovaldate>25/09/2014</ethicapprovaldate>
      <hrec>AHS/37/14/HREC</hrec>
      <ethicsubmitdate>22/07/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Allan Cripps</name>
      <address>Griffith Health Centre, Griffith University, Gold Coast Campus, Parklands, QLD 4222</address>
      <phone>+61 7 5678 0809</phone>
      <fax />
      <email>allan.cripps@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicholas west</name>
      <address>Griffith Health Centre, Griffith University, Gold Coast Campus, Parklands, QLD 4222</address>
      <phone>+61419649447</phone>
      <fax />
      <email>n.west@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicholas west</name>
      <address>Griffith Health Centre, Griffith University, Gold Coast Campus, Parklands, QLD 4222</address>
      <phone>+61419649447</phone>
      <fax />
      <email>n.west@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicholas west</name>
      <address>Griffith Health Centre, Griffith University, Gold Coast Campus, Parklands, QLD 4222</address>
      <phone>+61419649447</phone>
      <fax />
      <email>n.west@griffith.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>